A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation

M. J. Hjermstad (Corresponding Author), H. Knobel, L. Brinch, Peter Fayers, J. H. Loge, H. Holte, S. Kaasa

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Health-related quality of life( HRQOL), fatigue and psychological distress were prospectively assessed in 248 cancer patients treated with allogeneic (SCT, N = 61), or autologous (ASCT, N = 69) stem cell transplantation or conventional chemotherapy (CT, N = 118) of whom 128 completed the assessments after 3 years. The European Organization for Treatment and Research of Cancer Core Quality of Life Questionnaire and the Hospital Anxiety and Depression Scale were administered nine (SCT/ ASCT groups) or seven times ( CT group) during the first year. The Fatigue Questionnaire was added at the final assessment. The SCT group displayed greater changes from baseline scores than the ASCT group, with more symptoms in the first months post transplant. A gradual improvement was found in both groups during the following 4 - 6 months, before stabilizing at baseline levels. Only minor changes were observed after the first year. All groups reported more fatigue than the population values after 3 years (P<0.01). The ASCT group also reported less optimal HRQOL (P<0.01 - 0.0001). No differences were found in anxiety and depression. Despite a faster recovery during the first months after transplant, the ASCT patients reported poorer functioning and more fatigue compared to the SCT group after 3 years. This suggests a need for a closer follow-up of these patients with special emphasis on functional status and fatigue.

Original languageEnglish
Pages (from-to)257-266
Number of pages10
JournalBone Marrow Transplantation
Volume34
DOIs
Publication statusPublished - 2004

Keywords

  • health-related quality of life
  • EORTC QLQ-C30
  • HADS
  • fatigue
  • high-dose chemotherapy
  • prospective study
  • BONE-MARROW-TRANSPLANTATION
  • LONG-TERM SURVIVORS
  • GENERAL NORWEGIAN POPULATION
  • HODGKINS-DISEASE SURVIVORS
  • CANCER-PATIENTS
  • LATE COMPLICATIONS
  • HOSPITAL ANXIETY
  • FOLLOW-UP
  • EUROPEAN-ORGANIZATION
  • SCALE

Cite this

A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. / Hjermstad, M. J. (Corresponding Author); Knobel, H.; Brinch, L.; Fayers, Peter; Loge, J. H.; Holte, H.; Kaasa, S.

In: Bone Marrow Transplantation, Vol. 34, 2004, p. 257-266.

Research output: Contribution to journalArticle

Hjermstad, M. J. ; Knobel, H. ; Brinch, L. ; Fayers, Peter ; Loge, J. H. ; Holte, H. ; Kaasa, S. / A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. In: Bone Marrow Transplantation. 2004 ; Vol. 34. pp. 257-266.
@article{a829423eb646462e89e79254856a5903,
title = "A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation",
abstract = "Health-related quality of life( HRQOL), fatigue and psychological distress were prospectively assessed in 248 cancer patients treated with allogeneic (SCT, N = 61), or autologous (ASCT, N = 69) stem cell transplantation or conventional chemotherapy (CT, N = 118) of whom 128 completed the assessments after 3 years. The European Organization for Treatment and Research of Cancer Core Quality of Life Questionnaire and the Hospital Anxiety and Depression Scale were administered nine (SCT/ ASCT groups) or seven times ( CT group) during the first year. The Fatigue Questionnaire was added at the final assessment. The SCT group displayed greater changes from baseline scores than the ASCT group, with more symptoms in the first months post transplant. A gradual improvement was found in both groups during the following 4 - 6 months, before stabilizing at baseline levels. Only minor changes were observed after the first year. All groups reported more fatigue than the population values after 3 years (P<0.01). The ASCT group also reported less optimal HRQOL (P<0.01 - 0.0001). No differences were found in anxiety and depression. Despite a faster recovery during the first months after transplant, the ASCT patients reported poorer functioning and more fatigue compared to the SCT group after 3 years. This suggests a need for a closer follow-up of these patients with special emphasis on functional status and fatigue.",
keywords = "health-related quality of life, EORTC QLQ-C30, HADS, fatigue, high-dose chemotherapy, prospective study, BONE-MARROW-TRANSPLANTATION, LONG-TERM SURVIVORS, GENERAL NORWEGIAN POPULATION, HODGKINS-DISEASE SURVIVORS, CANCER-PATIENTS, LATE COMPLICATIONS, HOSPITAL ANXIETY, FOLLOW-UP, EUROPEAN-ORGANIZATION, SCALE",
author = "Hjermstad, {M. J.} and H. Knobel and L. Brinch and Peter Fayers and Loge, {J. H.} and H. Holte and S. Kaasa",
year = "2004",
doi = "10.1038/sj.bmt.1704561",
language = "English",
volume = "34",
pages = "257--266",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation

AU - Hjermstad, M. J.

AU - Knobel, H.

AU - Brinch, L.

AU - Fayers, Peter

AU - Loge, J. H.

AU - Holte, H.

AU - Kaasa, S.

PY - 2004

Y1 - 2004

N2 - Health-related quality of life( HRQOL), fatigue and psychological distress were prospectively assessed in 248 cancer patients treated with allogeneic (SCT, N = 61), or autologous (ASCT, N = 69) stem cell transplantation or conventional chemotherapy (CT, N = 118) of whom 128 completed the assessments after 3 years. The European Organization for Treatment and Research of Cancer Core Quality of Life Questionnaire and the Hospital Anxiety and Depression Scale were administered nine (SCT/ ASCT groups) or seven times ( CT group) during the first year. The Fatigue Questionnaire was added at the final assessment. The SCT group displayed greater changes from baseline scores than the ASCT group, with more symptoms in the first months post transplant. A gradual improvement was found in both groups during the following 4 - 6 months, before stabilizing at baseline levels. Only minor changes were observed after the first year. All groups reported more fatigue than the population values after 3 years (P<0.01). The ASCT group also reported less optimal HRQOL (P<0.01 - 0.0001). No differences were found in anxiety and depression. Despite a faster recovery during the first months after transplant, the ASCT patients reported poorer functioning and more fatigue compared to the SCT group after 3 years. This suggests a need for a closer follow-up of these patients with special emphasis on functional status and fatigue.

AB - Health-related quality of life( HRQOL), fatigue and psychological distress were prospectively assessed in 248 cancer patients treated with allogeneic (SCT, N = 61), or autologous (ASCT, N = 69) stem cell transplantation or conventional chemotherapy (CT, N = 118) of whom 128 completed the assessments after 3 years. The European Organization for Treatment and Research of Cancer Core Quality of Life Questionnaire and the Hospital Anxiety and Depression Scale were administered nine (SCT/ ASCT groups) or seven times ( CT group) during the first year. The Fatigue Questionnaire was added at the final assessment. The SCT group displayed greater changes from baseline scores than the ASCT group, with more symptoms in the first months post transplant. A gradual improvement was found in both groups during the following 4 - 6 months, before stabilizing at baseline levels. Only minor changes were observed after the first year. All groups reported more fatigue than the population values after 3 years (P<0.01). The ASCT group also reported less optimal HRQOL (P<0.01 - 0.0001). No differences were found in anxiety and depression. Despite a faster recovery during the first months after transplant, the ASCT patients reported poorer functioning and more fatigue compared to the SCT group after 3 years. This suggests a need for a closer follow-up of these patients with special emphasis on functional status and fatigue.

KW - health-related quality of life

KW - EORTC QLQ-C30

KW - HADS

KW - fatigue

KW - high-dose chemotherapy

KW - prospective study

KW - BONE-MARROW-TRANSPLANTATION

KW - LONG-TERM SURVIVORS

KW - GENERAL NORWEGIAN POPULATION

KW - HODGKINS-DISEASE SURVIVORS

KW - CANCER-PATIENTS

KW - LATE COMPLICATIONS

KW - HOSPITAL ANXIETY

KW - FOLLOW-UP

KW - EUROPEAN-ORGANIZATION

KW - SCALE

U2 - 10.1038/sj.bmt.1704561

DO - 10.1038/sj.bmt.1704561

M3 - Article

VL - 34

SP - 257

EP - 266

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -